Factor Therapeutics is an Australian biotechnology company pursuing the development and commercialisation of advanced wound care therapeutics.

The Company’s lead program, VF-001, is a targeted growth factor that is being developed to treat venous leg ulcers (VLUs). Chronic wounds, such as VLUs, are common, painful and debilitating – a silent epidemic.

Factor Therapeutics is a public company traded on the Australian Securities Exchange (ASX:FTT).